In conclusion, MAGL has a central function in the endocannabinoid system, and MAGL inhibitors are promising therapeutic agents for various disorders, including inflammation, neurodegeneration, metabolic disorders, and even cancers. The gene discussed is MGLL; the disease is metabolic disease.